Arrow
Arrow
Slider

Premaitha Health PLC
(“Premaitha” or the “Company”)

Premaitha Raises Awareness of the IONA® Test at Key International Medical Events

Manchester, UK – 13 March 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, will be attending a series of key international fetal medicine and OB/GYN events during March to broaden awareness of the IONA® test. The events will include:

The Royal College of Obstetricians and Gynaecologists (RCOG) World Congress 2017

The RCOG World Congress 2017 will be held in Cape Town, South Africa between 20 - 22 March 2017. Premaitha will host an exhibition booth showcasing the IONA® test to a large number of obstetrician and gynaecologist professionals from around the world. For further details, visit: www.rcog2017.com.

Forum Labo

Forum Labo will be held in Paris, France between 28 - 30 March 2017. Executives from Premaitha will attend this event together with the Company’s French distributor, Adgenix, to promote the benefits of the IONA® test to the large number of laboratory professionals from France that will be in attendance. For further details, visit: www.forumlabo.com.

The British Maternal and Fetal Medicine Society (BMFMS), 19th Annual Conference

The BMFMS 19th Annual Conference will be held in Amsterdam, The Netherlands between 30 – 31 March 2017. As a Gold Sponsor, Premaitha will have a significant presence at the event, hosting an exhibition booth and an educational symposium on non-invasive prenatal screening. The delegates will hear from three key opinion leaders – who are also Premaitha customers - discussing different topics relating to the IONA® test. The speakers will include leading obstetricians:
•    Dr Asma Khalil from St George’s NHS Hospital;
•    Dr Francois Jacquemard from the American Hospital in Paris; and
•    Dr Kelly Cohen from Leeds NHS Teaching Hospital Trust.

In addition, there will be two clinical posters presented by two further IONA® test clinicians from the UK. For further details, visit: www.bmfmsconference.ukevents.org.

The 7th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE)

ASPIRE 2017 will be held in Kuala Lumpur, Malaysia between 30 March – 2 April 2017. Premaitha will host an exhibition booth in partnership with the Company’s Malaysian distributor, Analisa Scientific, showcasing the IONA® test to the region’s clinicians, nurses, researchers and academics operating in the field of reproductive medicine and fertility. For further details, visit: www.aspire2017.com.

Dr Stephen Little, CEO of Premaitha Health, commented: “Raising awareness of the superiority of the IONA® test among the international OB/GYN community is key to helping drive samples to our customers’ laboratories. March is expected to be a very busy month in the ongoing educational programme.”

For more information, please contact:

Premaitha Health PLC    
Dr Stephen Little, Chief Executive Officer    
Barry Hextall, Chief Financial Officer    
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0) 161 667 6865
    
Vigo Communications    
Ben Simons / Fiona Henson / Antonia Pollock    
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0) 20 7830 9700

About Premaitha

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group’s primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.

Premaitha’s IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample – which contains traces of fetal DNA – and estimates the risk of a fetus being affected with Down’s syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha’s IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia – the world's fastest growing NIPT market – as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

  • 19 May 2017 - Premaitha welcomes NIPT recommendation in France +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)
     
    Premaitha welcomes NIPT recommendation in France
     
    Haute Authorité de Santé recommends introduction of NIPT for high and intermediate risk women
     
    Manchester, UK – 19 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international molecular diagnostics group focused on prenatal testing, welcomes the recommendation by the Haute Authorité de Santé (“HAS”), the French National Authority for Health, to make non-invasive prenatal
    Read More
  • 12 May 2017 - Update Re. Swiss Customer +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Update Re. Swiss Customer

    Manchester, UK – 12 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international molecular diagnostics group focused on prenatal testing, announces that the Company’s application for its Swiss customer, Genoma SA (“Genoma”), to be placed into bankruptcy for non-payment of debts has been successful (the “Ruling”).

    As previously announced in the Company’s interim results (see RNS announcement on 21

    Read More
  • 13 March 2017 - Premaitha Raises Awareness of the IONA® Test at Key International Medical Events +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha Raises Awareness of the IONA ® Test at Key International Medical Events

    Manchester, UK – 13 March 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, will be attending a series of key international fetal medicine and OB/GYN events during March to broaden awareness of the IONA ® test. The events will include:

    The Royal College of Obstetricians and Gynaecologists

    Read More
  • 27 February 2017 - Completion of Yourgene Acquisition, Issue of Shares and Director Appointments +

    Premaitha Health PLC
    (“Premaitha” or the “Company” or the “Group”)

    Completion of Yourgene Acquisition, Issue of Shares and Director Appointments

    Manchester, UK – 27 February 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, announces regulatory clearance for the completion of the acquisition of Yourgene Bioscience Co., Ltd (“Yourgene”).

    The acquisition of Yourgene, announced on 21 December 2016, has now received regulatory clearance as required by Taiwanese law. 

    Read More
  • 20 February 2017 - Middle East Business Update +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Middle East Business Update

    Manchester, UK – 20 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, is pleased to announce significant commercial progress in the Middle East through its distribution network.

    Premaitha has appointed distributors across the Middle East and these partners have signed a number of new Middle Eastern customers which in aggregate are expected to generate over 10,000

    Read More
  • 16 February 2017 - Publication of scientific paper on Premaitha’s IONA® test +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Publication of scientific paper on Premaitha’s IONA ® test

    Manchester, UK – 16 February 2017 : Premaitha Health, developer of a leading CE-marked non-invasive prenatal screening system, is pleased to announce the publication of “ The IONA® Test: Development of an Automated Cell-Free DNA-Based Screening Test for Fetal Trisomies 13, 18, and 21 That Employs the Ion Proton Semiconductor Sequencing Platform ” in Fetal Diagnosis and Therapy.

    The paper

    Read More
  • 15 February 2017 - Issue of Equity +

    Premaitha Health plc
    ("Premaitha" or the "Company")

    Issue of Equity

    Manchester, UK - 15 February 2017: Premaitha Health plc (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces that it has agreed to issue to Harwood Capital ("Harwood") 17,000,000 new ordinary shares of 0.1 pence per share, subject to admission to AIM, raising £1,487,500 at a price of 8.75 pence per share. Following the allotment of the shares, Harwood's holding will represent 6.9%

    Read More
  • 13 February 2017 - New partnership with major European diagnostics group +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    New partnership with major European diagnostics group

    Manchester, UK – 13 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces a partnership with a major international diagnostics services group to implement the IONA ® test in at least two laboratories.

    Premaitha, through its distribution network, has secured a four-year Master Procurement Agreement (the “MPA”) with a major European diagnostics services

    Read More
  • 7 February 2017 - Southern Europe Business Update +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Southern Europe Business Update

    Manchester, UK – 7 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces a number of new customers through its distribution network in Southern Europe.

    Italy
    Premaitha’s Italian distributor has won a public hospital tender to implement the first public non-invasive prenatal testing (“NIPT”) programme in southern Italy. The hospital will act as a regional hub

    Read More
  • 21 December 2016 - Conditional Acquisition of Yourgene Bioscience and Posting of Circular +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Wednesday, 21 December 2016

    Premaitha Health PLC
    (“Premaitha” or “the Company”)

    Conditional Acquisition of Yourgene Bioscience and Posting of Circular

    Manchester, UK – 21 December 2016: Premaitha Health PLC (AIM: NIPT), developer of a leading CEmarked non-invasive prenatal screening system (“NIPT”), announces the conditional acquisition of Yourgene Bioscience Co., Ltd (“Yourgene”) (the”Acquisition”), a significant NIPT provider in Asia and the posting shortly of a circular convening

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Investor Relations
Ben Simons / Fiona Henson
Vigo Communications
180 Piccadilly
London W1J 9HF
premaitha@vigocomms.com
T : +44 (0) 20 7830 9700

Public Relations
Sophie Burness / Ellie Scott
Kindred Agency
4th Floor, Dean Bradley House
52 Horseferry Road
London SW1P 2AF
IONAcampaigns@kindredagency.com
T : +44 (0) 20 7830 9700

Two business people looking at computer screen